Financials data is unavailable for this security.
Cash flow in SEKView more
In 2023, cash reserves at Ascelia Pharma AB fell by 127.70m. However, Cash Flow from Investing totalled 47.00k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 126.79m for operations while cash used for financing totalled 936.00k.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.9554 |
---|---|
Tangible book value per share | -0.1881 |
More ▼
Balance sheet in SEKView more
Current ratio | 2.70 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.7144 |
---|---|
Total debt/total capital | 0.4167 |
More ▼